BR112021016448A2 - Composto derivado heterocíclico inovador e uso do mesmo - Google Patents

Composto derivado heterocíclico inovador e uso do mesmo

Info

Publication number
BR112021016448A2
BR112021016448A2 BR112021016448A BR112021016448A BR112021016448A2 BR 112021016448 A2 BR112021016448 A2 BR 112021016448A2 BR 112021016448 A BR112021016448 A BR 112021016448A BR 112021016448 A BR112021016448 A BR 112021016448A BR 112021016448 A2 BR112021016448 A2 BR 112021016448A2
Authority
BR
Brazil
Prior art keywords
innovative
heterocyclic derivative
derivative compound
compounds
homologous
Prior art date
Application number
BR112021016448A
Other languages
English (en)
Inventor
Young Gil Ahn
Dong Jin Hong
Ji Young Hwang
Seung Hyun Jung
Seo Hee Kim
Chang Hee Park
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of BR112021016448A2 publication Critical patent/BR112021016448A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto derivado heterocíclico inovador e uso do mesmo. a presente revelação se refere a compostos derivados heterocíclicos inovadores e ao uso dos mesmos e, mais particularmente, a compostos derivados heterocíclicos inovadores que têm atividade inibitória contra ezh1 (potenciador de zeste homólogo 1) e/ou ezh2 (potenciador de zeste homólogo 2), sais farmaceuticamente aceitáveis dos mesmos ou composições farmacêuticas que contêm esses compostos.
BR112021016448A 2019-02-19 2020-02-19 Composto derivado heterocíclico inovador e uso do mesmo BR112021016448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190019544A KR20200101219A (ko) 2019-02-19 2019-02-19 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
PCT/KR2020/002427 WO2020171606A1 (ko) 2019-02-19 2020-02-19 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도

Publications (1)

Publication Number Publication Date
BR112021016448A2 true BR112021016448A2 (pt) 2021-11-09

Family

ID=72144293

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016448A BR112021016448A2 (pt) 2019-02-19 2020-02-19 Composto derivado heterocíclico inovador e uso do mesmo

Country Status (17)

Country Link
US (1) US20220135582A1 (pt)
EP (1) EP3929199A4 (pt)
JP (1) JP7358491B2 (pt)
KR (1) KR20200101219A (pt)
CN (1) CN113423710B (pt)
AU (1) AU2020226042B2 (pt)
BR (1) BR112021016448A2 (pt)
CA (1) CA3130456C (pt)
CL (1) CL2021002165A1 (pt)
EA (1) EA202191991A1 (pt)
IL (1) IL285604A (pt)
MX (1) MX2021009854A (pt)
PE (1) PE20211703A1 (pt)
SG (1) SG11202108940RA (pt)
TW (1) TWI829869B (pt)
WO (1) WO2020171606A1 (pt)
ZA (1) ZA202105970B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PE20230732A1 (es) * 2020-08-13 2023-05-03 Hanmi Pharmaceutical Co Ltd Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
WO2022179584A1 (zh) * 2021-02-26 2022-09-01 南京药石科技股份有限公司 新型ezh2抑制剂及其用途
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
TW202400602A (zh) * 2022-05-31 2024-01-01 大陸商和記黃埔醫藥（上海）有限公司 三環類化合物及其用途
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
CN115974856B (zh) * 2022-12-28 2023-08-11 北京康立生医药技术开发有限公司 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9822103B2 (en) * 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
NZ723312A (en) * 2014-03-17 2019-10-25 Daiichi Sankyo Co Ltd 1,3-benzodioxole derivative
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
CR20200484A (es) * 2014-06-17 2021-04-26 Pfizer COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
WO2016154434A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of California Selective alpha-7 nicotinic receptor agonists and methods for making and using them
CA3100977A1 (en) * 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
MX2021009854A (es) 2021-09-28
EP3929199A1 (en) 2021-12-29
EP3929199A4 (en) 2022-10-26
AU2020226042B2 (en) 2022-07-14
WO2020171606A1 (ko) 2020-08-27
IL285604A (en) 2021-09-30
AU2020226042A1 (en) 2021-09-09
SG11202108940RA (en) 2021-09-29
JP7358491B2 (ja) 2023-10-10
PE20211703A1 (es) 2021-09-01
CA3130456C (en) 2023-10-03
CN113423710A (zh) 2021-09-21
US20220135582A1 (en) 2022-05-05
KR20200101219A (ko) 2020-08-27
EA202191991A1 (ru) 2021-12-10
TW202045512A (zh) 2020-12-16
CL2021002165A1 (es) 2022-04-22
JP2022522648A (ja) 2022-04-20
CN113423710B (zh) 2024-06-14
ZA202105970B (en) 2023-05-31
TWI829869B (zh) 2024-01-21
CA3130456A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
BR112021016448A2 (pt) Composto derivado heterocíclico inovador e uso do mesmo
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
PH12020551751A1 (en) 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting asm activity, and use thereof
MX2019006843A (es) Inhibidor de cdk4/6.
CR20220251A (es) Nuevos derivados de metilquinazolinona
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
BR112018074985A2 (pt) composições antibacterianas
WO2021094904A3 (en) 4-(4-(4,5-dihydroisoxazol-3-yl)thiazol-2-yl) piperidine sulfilimine and sulfoximine derivatives and related compounds as fungicides for crop protection
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
BR112021011325A2 (pt) Derivados de rapamicina
BR112021019817A2 (pt) Compostos de pirrol
MX2021014680A (es) Derivado de benzotriazol.
AU2019322713A8 (en) Novel medicament for treating inflammatory bowel disease
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
BR112022006608A2 (pt) Inibidores orais do fator d do complemento
PH12020551342A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
SG11201907945YA (en) Azetidine derivative
EA202190316A1 (ru) Конденсированное производное лактама
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]